AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17353866
Drug: Thyroid hormone
RxNorm normalized name: Thyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormone treatment
Trial: 3894871
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g of glucose (G)
Trial: 3894871
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g of fructose (F)
Trial: 28475473
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplement (50,000 units, one every fortnight for 8 weeks)
Trial: 26306589
Drug: Urinary Magnesium
RxNorm normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary Magnesium to Creatinine ratio (Mg/Cr)
Trial: 1986602
Drug: Fluoxetine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine administration
Trial: 12841498
Drug: Mycobacterium w
RxNorm normalized name: Mycobacterium W Vaccine
DrugBank: Mycobacterium w. Vaccine (DB15798)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycobacterium w (immuvac) as adjuvant therapy
Trial: 12841498
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (cisplatin and etoposide) and radiotherapy (control group)
Trial: 8862741
Drug: Fluid and
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid and salt supplementation (0.1 g sodium chloride/kg body weight and 30 mL water/kg body weight) during hypokinesia
Trial: 1284152
Drug: Gallopamil (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil (0.4 mg)
Trial: 3890508
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin followed by oral warfarin
Trial: 9784040
Drug: Terbinafine (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine (125 or 250 mg/day) for 1 week
Trial: 9784040
Drug: Terbinafine (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine (125 or 250 mg/day) for 2 weeks
Trial: 9784040
Drug: Terbinafine (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine (125 or 250 mg/day) for 4 weeks
Trial: 8112206
Drug: Fibrin injection
RxNorm normalized name: thrombin
DrugBank: Fibrin (DB16604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin injection (with adrenalin: n = 11; without adrenalin: n = 29)
Trial: 8112206
Drug: Polidocanol injection
RxNorm normalized name: polidocanol Injection
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polidocanol injection (with adrenalin: n = 17; without adrenalin: n = 8)
Trial: 8112206
Drug: Adrenalin injection
RxNorm normalized name: epinephrine Injection [Adrenalin]
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adrenalin injection alone (n = 15)
Trial: 2481163
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Nifedipine and Metoprolol
Trial: 2468838
Drug: Nifedipine (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (in patients already on beta-blocker)
Trial: 11286323
Drug: tolterodine L‐tartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolterodine L‐tartrate ER 8 mg (2 x 4 mg capsules) with a standardised high‐fat breakfast
Trial: 11286323
Drug: tolterodine L‐tartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolterodine L‐tartrate ER 8 mg (2 x 4 mg capsules) on an empty stomach
Trial: 11286323
Drug: tolterodine L‐tartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolterodine L‐tartrate IR 4 mg (2 x 2 mg tablets) administered in the fasting state
Trial: 30099530
Drug: Statin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin with a run-in period (test dose)
Trial: 30099530
Drug: Statin without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin without a run-in period (no test dose)
Trial: 25895202
Drug: 400 IU
RxNorm normalized name: Vitamin D 400 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 IU of vitamin D + 600 mg of calcium lactate (VD-Ca group)
Trial: 25895202
Drug: Multiple micronutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrients with 400 IU of vitamin D + 600 mg of calcium lactate (MMN-VD-Ca group)
Trial: 11136298
Drug: Rifampicin 600
RxNorm normalized name: Rifampicin 600 mg powder for solution for infusion vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 600 mg once daily for 5 days
Trial: 15297200
Drug: Topotecan (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan (1.0 mg/m(2)/day on days 1 to 3) and Carboplatin (AUC 4 on day 1) followed by Paclitaxel (175 mg/m(2) via 3‐h IV infusion on day 1) and Carboplatin (AUC 5 on day 1)
Trial: 24619991
Drug: Prenatal Qi
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal Qi exercise (90 minutes, twice a week for 12 weeks)
Trial: 23708168
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (hemoglobin level ≥10 g/dL)
Trial: 23708168
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (hemoglobin <8 g/dL or symptoms from anemia)
Trial: 21387981
Drug: Oral irrigator
RxNorm normalized name: Irrigation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral irrigator with prototype jet tip
Trial: 21387981
Drug: Oral irrigator
RxNorm normalized name: Irrigation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral irrigator with standard jet tip
Trial: 15570285
Drug: Hydroxyurea (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (30 mg/kg/day)
Trial: 15570285
Drug: Busulphan (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Busulphan (0.1 mg/kg/day)
Trial: 11122135
Drug: 10 microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 microg/kg G‐CSF once daily (n = 25)
Trial: 11122135
Drug: 5 microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 microg/kg G‐CSF twice daily (n = 25)
Trial: 27212247
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) treatment (15‐20mg/kg/day) for 24 weeks
Trial: 24697979
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of naproxen 500 mg and apixaban 10 mg
Trial: 19045972
Drug: Wait-list control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wait-list control group (no treatment during intervention period)
Trial: 10630793
Drug: AIK-C vaccine
RxNorm normalized name: Meningococcal polysaccharide vaccine group C
DrugBank: Meningococcal polysaccharide vaccine group C (DB13890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIK-C vaccine
Trial: 10630793
Drug: Schwarz vaccine
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwarz vaccine
Trial: 7717832
Drug: Adjusted dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted dose heparin
Trial: 22295884
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (75 mg)
Trial: 2044396
Drug: Pethidine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine (75 mg)
Trial: 7314025
Drug: Intravenous salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous salbutamol and aminophylline
Trial: 23123509
Drug: nab-P/C (nab-paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-P/C (nab-paclitaxel 100 mg/m² weekly)
Trial: 23123509
Drug: sb-P/C (solvent-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sb-P/C (solvent-based paclitaxel 200 mg/m² day 1 every 3 weeks)
Trial: 11123451
Drug: Itraconazole oral
RxNorm normalized name: itraconazole Oral Tablet
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole oral solution
Trial: 9463082
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of serum IgG class anti-CMV antibodies in women following spontaneous abortions (n=11)
Trial: 9463082
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of serum IgG class anti-HPV-B19 antibodies in women following spontaneous abortions (n=11)
Trial: 9463082
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of IgM and IgG class antibodies against CMV and HPV-B19 in one patient
Trial: 2195714
Drug: Nimodipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (30 mg q.i.d. for 28 days)
Trial: 2195714
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical tablets for 28 days)
Trial: 29777529
Drug: ADS-5102 (210,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADS-5102 (210, 274, or 338 mg)
Trial: 28203003
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (medication group, low dose aspirin)
Trial: 15090564
Drug: Subcutaneous IFN
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous IFN beta‐1a, 22 micro g once weekly
Trial: 11715631
Drug: Rob 10
RxNorm normalized name: carob 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rob 10 (3 x 25 drops daily)
Trial: 8087826
Drug: Nitroglycerin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin infusion for 24 hours
Trial: 8087826
Drug: N-acetylcysteine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine administration after nitroglycerin infusion
Trial: 31370954
Drug: RAS inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAS inhibitors
Trial: 25345681
Drug: Daily sessions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily sessions of music-guided slow-breathing (<10 breaths/min) for 30 minutes
Trial: 18623908
Drug: Maraviroc (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maraviroc (300 mg twice a day)
Trial: 12640507
Drug: Trandolapril (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril (2 to 4 mg/day)
Trial: 12640507
Drug: Captopril (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (75 to 150 mg/day)
Trial: 1831633
Drug: Ondansetron (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (0.15 mg/kg, three intravenous doses 4-hourly)
Trial: 1831633
Drug: Metoclopramide (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (2.0 mg/kg, six intravenous doses)
Trial: 1831633
Drug: Oral Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Ondansetron (16 mg t.d.s.)
Trial: 6346845
Drug: Ethmozine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethmozine (mean total daily dose of 830 mg +/- 318 mg, dosing every 8 hours)
Trial: 18682410
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml ropivacaine 0.5%
Trial: 18682410
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml ropivacaine 0.5%
Trial: 27396224
Drug: Ketamine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.25 mg/kg (Group K, n = 91)
Trial: 22143524
Drug: Tigecycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tigecycline (100 mg loading dose followed by 50 mg every 12 h for a minimum of 7 days)
Trial: 9571385
Drug: ASPD+ (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASPD+ (180 days treatment)
Trial: 9571385
Drug: AABS+ (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AABS+ (180 days treatment)
Trial: 9571385
Drug: ASPD+ (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASPD+ (90 days treatment)
Trial: 9571385
Drug: AABS+ (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AABS+ (90 days treatment)
Trial: 26014295
Drug: Androgen-deprivation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen-deprivation therapy (ADT) with radiotherapy (RT)
Trial: 22008927
Drug: Daily media
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily media habits of smokers
Trial: 17892034
Drug: Continuous transdermal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous transdermal hormonal therapy with 17beta‐estradiol (0.05 mg/24 hours) and oral dydrogesterone (5 mg daily)
Trial: 17892034
Drug: Continuous transdermal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous transdermal hormonal therapy with 17beta‐estradiol (0.05 mg/24 hours) and oral medroxyprogesterone (5 mg daily)
Trial: 9459623
Drug: Euthyroid at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euthyroid at drug withdrawal
Trial: 7491892
Drug: Fried onions
RxNorm normalized name: ONION
DrugBank: Onion (DB10548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fried onions (rich in quercetin glucosides) equivalent to 89 mg aglycone
Trial: 7491892
Drug: Pure quercetin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pure quercetin rutinoside equivalent to 100 mg aglycone
Trial: 7491892
Drug: Pure quercetin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pure quercetin aglycone equivalent to 100 mg
Trial: 2128072
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of EDTA and sugar tests
Trial: 31228675
Drug: Intravenous intralipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous intralipid (2 doses of 20% solution, 4 ml diluted in 250 ml normal saline)
Trial: 24742182
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at local acupoints in combination with distal acupoint
Trial: 24742182
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at local acupoints in combination with distal non-acupoint
Trial: 24742182
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at local non-acupoints in combination with distal acupoint
Trial: 24742182
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at local non-acupoints in combination with distal non-acupoint
Trial: 20097934
Drug: Dapoxetine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapoxetine (single and multiple dosing)
Trial: 19068724
Drug: Intravesical instillation
RxNorm normalized name: ADSTILADRIN Suspension for Intravesical Instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of epirubicin (40 mg in 40 ml saline) once every two weeks for 3 months starting one week after TURBT (Group A)
Trial: 19068724
Drug: Intravesical instillation
RxNorm normalized name: ADSTILADRIN Suspension for Intravesical Instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of epirubicin (40 mg in 40 ml saline) once every two weeks for 3 months starting 6 months after TURBT (Group B)
Trial: 15854872
Drug: Reformulated cognitive-behavioral
RxNorm normalized name: Tarsum Reformulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reformulated cognitive-behavioral (RCB) treatment
Trial: 15854872
Drug: Standard behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard behavioral (SB) treatment
Trial: 12814527
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 (PGE2) 3 mg vaginal pessary in two doses 6 hourly
Trial: 12814527
Drug: Extra-amniotic saline
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-amniotic saline infusion (EASI) with simultaneous intravenous oxytocin infusion for 12 hours
Trial: 2246997
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine preparation
Trial: 2246997
Drug: Clonidine (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (oral or transdermal)
Trial: 7425917
Drug: 1 drop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop of the optimal combination
Trial: 7425917
Drug: 2 drops
RxNorm normalized name: CHOLECALCIFEROL 12.5 ug in 0.04 mL / MENAQUINONE 7 50 ug in 0.04 mL ORAL SOLUTION/ DROPS [YYUX Organic Liquid Vitamin D3 plus K2 Drops]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 drops of the optimal combination
Trial: 25557838
Drug: Zanamivir (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanamivir (10 mg daily prophylaxis)
Trial: 25557838
Drug: Trivalent split
RxNorm normalized name: INFLUENZA VIRUS,TRIVALENT SPLIT VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent split virus influenza vaccine
Trial: 25557838
Drug: Both zanamivir
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Both zanamivir and vaccine
Trial: 19330567
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron sulphate
Trial: 11465336
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of placebo gel (Group I)
Trial: 11465336
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of 2% lidocaine gel (Group II)
Trial: 11465336
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 2% lidocaine gel (Group III)
Trial: 9766721
Drug: Endorectal coil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endorectal coil (ERC) at 60, 100, and 140 ml balloon inflation
Trial: 8143427
Drug: Fed state
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fed state (after a meal containing 80 g of fat and 80 g of carbohydrate)
Trial: 2974418
Drug: 5'dFUR (doxifluridine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5'dFUR (doxifluridine) 2 g.m-2
Trial: 2974418
Drug: 5'dFUR (doxifluridine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5'dFUR (doxifluridine) 4 g.m-2
Trial: 30102652
Drug: Fluconazole 1200 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 1200 mg/day
Trial: 24901857
Drug: MPSS alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPSS alone (30 mg/kg initially and 5.4 mg/kg every hour till 23 hours if admitted within 3 hours and till 47 hours if recruited within 3-6 hours)
Trial: 18926059
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg twice a day for 6 weeks)
Trial: 16408169
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg diclofenac suppository
Trial: 28783865
Drug: Capsule A
RxNorm normalized name: capsule administration aid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule A (4 mg)
Trial: 28783865
Drug: Capsule B
RxNorm normalized name: Emend 80mg Capsule BiPack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule B (4 mg)
Trial: 27310949
Drug: Lowest TA-SUA
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest TA-SUA group (<5.5 mg/dL)
Trial: 27310949
Drug: Middle 3
RxNorm normalized name: WHEAT MIDDLINGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle 3 TA-SUA groups (5.5-8.4 mg/dL)
Trial: 27310949
Drug: Highest TA-SUA
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest TA-SUA group (≥8.5 mg/dL)
Trial: 22718556
Drug: 0.4 µg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 µg/kg/min PGE(2) (Prostin(®)E2, dinoprostone)
Trial: 16989901
Drug: Ruboxistaurin (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruboxistaurin (32 mg/day)
Trial: 16353319
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg 17beta‐E2/0.5 mg NETA
Trial: 16353319
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg 17beta‐E2/1 mg NETA
Trial: 9786602
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blockers (nisoldipine or benidipine)
Trial: 9786602
Drug: Angiotensin converting
RxNorm normalized name: Angiotensin converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin converting enzyme inhibitors (ACEI) (captopril or imidapril)
Trial: 9786602
Drug: Beta-receptor blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-receptor blockers (arotinolol or bisoprolol)